The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The medicine is now approved for eight indications across five different types of cancer in China.
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
